Company profile

Ticker
SMTI
Exchange
Website
CEO
J. Michael Carmena
Employees
Incorporated in
Location
Fiscal year end
Former names
Inav Travel Corporation, MB Software Corp, Wound Management Technologies, Inc.
SEC CIK
IRS number
592220004

SMTI stock data

(
)

Calendar

12 May 20
3 Jul 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 3.02M 2.49M 47.54K 1.57M
Net income -351.42K -162.57K -486.92K -151.03K
Diluted EPS -0.15 -0.39 0 0
Net profit margin -11.65% -6.54% -1024% -9.64%
Operating income -323.13K -157.15K -467.55K -132K
Net change in cash -323.29K 10.61K 85.35K 186.97K
Cash on hand 419.16K 742.46K 731.85K 646.5K
Cost of revenue 334.83K 289.34K 22.62K 115.91K
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 5.84M 6.3M 5.51M 3.37M
Net income -600.57K 331.31K -415.75K -1.34M
Diluted EPS 0 0 -0.01 -0.02
Net profit margin -10.29% 5.25% -7.55% -39.75%
Operating income* -501.86K 120.44K -272.13K -964.98K
Net change in cash 268.66K -370.29K 651.14K -341.1K
Cash on hand 731.85K 463.19K 833.48K 182.34K
Cost of revenue 507.42K 806.04K 943.58K 891.97K

Financial data from company earnings reports. *Asterisk values are approximate.

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
27 Apr 20 Bowman Shawn M. Common Stock Grant Aquire A 0 1,000 0 17,065
24 Feb 20 Bowman Shawn M. Common Stock Grant Aquire A 0 13,555 0 16,065
24 Feb 20 Bowman Shawn M. Common Stock Grant Aquire A 0 1,000 0 2,510
24 Feb 20 Bowman Shawn M. Common Stock Grant Aquire A 0 1,510 0 1,510
24 Feb 20 Fleming Zachary B. Common Stock Grant Aquire A 0 13,555 0 18,105
24 Feb 20 Fleming Zachary B. Common Stock Grant Aquire A 0 4,550 0 4,550
24 Feb 20 Michael D. McNeil Common Stock Grant Aquire A 0 8,097 0 10,637
24 Feb 20 Michael D. McNeil Common Stock Grant Aquire A 0 2,540 0 2,540
24 Feb 20 Kenneth E Thorpe Common Stock Grant Aquire A 0 2,410 0 2,410
13F holders
Current Prev Q Change
Total holders 0 0 NaN%
Opened positions 0 0 NaN%
Closed positions 0 0 NaN%
Increased positions 0 0 NaN%
Reduced positions 0 0 NaN%
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Risks
  • We had a history of losses in prior years and may not maintain profitability as we expand our selling efforts.
  • Our revenue growth for a particular period is difficult to predict, and a shortfall in forecast revenues may harm our operating results.
  • If our products do not gain market acceptance, we might not be able to fund future operations.
  • Disruption of, or changes in, our distribution model or customer base could harm our sales and margins.
  • If we cannot meet our future capital requirements, our business will suffer.
  • Failure to retain and recruit key personnel would harm our ability to meet key objectives.
  • Failure to manage our planned growth could harm our business.
  • We operate in a highly competitive industry and face competition from large, well-established medical device manufacturers as well as new market entrants.
  • Security breaches and other disruptions could compromise our information and expose us to liability, which would cause our business and reputation to suffer.
  • We may not be able to maintain sufficient product liability insurance to cover claims against us.
  • Competitors could invent products superior to ours and cause our products and technologies to become obsolete.
  • We may have exposure to product liability claims.
  • We may be found to infringe on intellectual property rights of others.
  • Our business is affected by numerous regulations.
  • If we fail to obtain or experience significant delays in obtaining regulatory clearances or approvals to market future medical device products, we will be unable to commercialize these products until such clearance or approval is obtained.
  • Changes to the FDA clearance and approval processes or ongoing regulatory requirements could make it more difficult for us to obtain FDA clearance or, approval of new products or comply with ongoing requirements.
  • Modifications to our current products may require new marketing clearances or approvals or require us to cease marketing or recall the modified products until such clearances or approvals are obtained.
  • Changes in reimbursement policies and regulations by governmental or other third-party payers may have an adverse impact on the use of our products.
  • We and our sales personnel, whether employed by us or by others, must comply with various federal and state anti-kickback, self-referral, false claims and similar laws, any breach of which could cause a material adverse effect on our business.
  • The trading price of the shares of our common stock is highly volatile, and purchasers of our common stock could incur substantial losses.
  • Our common stock does not have a vigorous trading market and you may not be able to sell your securities when desired.
  • The potential sale of large amounts of common stock may have a negative effect upon the market value of our shares.
  • We have not paid, and we are unlikely to pay cash dividends on our securities in the near future.
  • A few of our existing shareholders own a large percentage of our voting stock and have control over matters requiring stockholder approval and may delay or prevent a change in control.
  • Our Board can authorize the issuance of preferred stock, which could diminish the rights of holders of our common stock and make a change of control of the Company more difficult even if it might benefit our shareholders.
Management Discussion
  • Revenues.  The Company generated revenues of $3,524,331 for the three months ended March 31, 2020, compared to revenues of $2,486,896 for the three months ended March 31, 2019, representing a 42% increase in revenues from prior year. The higher revenues in 2020 were primarily due to the continued execution of the Company’s strategy to expand its sales force and independent distribution network in both new and existing U.S. markets.
  • Cost of goods sold. Cost of goods sold for the three months ended March 31, 2020, was $330,188, compared to costs of goods sold of $289,340 for the three months ended March 31, 2019. The increase over prior year was due to the higher sales volume.
  • Selling, general and administrative expenses (“SG&A"). SG&A expenses for the three months ended March 31, 2020, were $4,906,538, as compared to SG&A expenses of $2,350,363 for the three months ended March 31, 2019. The higher SG&A expenses in 2020 were primarily due to increased payroll costs resulting from sales force expansion and operational support, higher sales commission expense as a result of higher product sales, and increased marketing costs related to promotional activities for new and existing product lines. Direct selling costs represented the vast majority of the increase in total SG&A costs as we increased the size of our field sales organization from nine in March 2019 to eighteen in March of 2020.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: ABF, absence, Acelity, ACell, adversely, Aid, assume, attached, attempt, award, AWC, bad, beauty, biopharmaceutical, caution, Chairman, civil, compensation, compete, competing, competitive, conformity, consulting, cosmetic, country, credentialed, currency, cut, declared, delay, depend, detailed, deterioration, discretionary, disposed, dispute, Division, DME, doubtful, durable, duration, economy, efficacy, eighteen, emergency, enhance, epidemic, eventually, experience, extensive, extent, external, federal, field, final, fixed, forecast, global, good, governmental, gradual, harm, highly, home, impairment, improvement, improving, Incentive, indeterminate, individual, instituted, insufficient, Integra, introduction, issuable, large, leading, length, lessening, litigation, long, manufacturer, manufacturing, marked, Medline, moderate, natural, negatively, Nephew, Nevada, notification, November, omitted, order, outbreak, outperform, overstated, pandemic, patient, Paycheck, penalty, people, personnel, plastic, plc, podiatry, political, portfolio, postponed, PPP, predict, proactively, professional, promptly, publicly, put, ranked, recipient, reconstructive, recover, recoverability, recoverable, refund, Relief, relieve, reopen, replacing, restricted, resumption, review, reviewed, run, serve, served, set, shipment, significantly, Similarly, situation, Smith, southeastern, specialty, spending, spine, spread, sum, superior, supplemental, supplemented, surgery, suspended, suspension, team, technical, temporary, terrorism, toiletry, trauma, travel, twelve, unaffiliated, unanticipated, uncertain, unclear, uncollectible, undiscounted, unexpected, unrecognized, unredacted, unrelated, unrest, unsecured, unvested, variety, vascular, vast, war, widespread, world, write
Removed: accelerated, accruing, affecting, beneficial, black, cease, Certificate, classification, classified, commencement, comparability, comparative, Condensed, contemplated, controlled, controlling, convert, curtail, deadlocked, default, deficit, derivative, disclose, discrepancy, discussed, encourage, existed, expired, expressed, extra, factor, feature, finance, gain, George, goal, governing, growth, highlight, historical, Howell, HRT, identified, iii, incorporating, inducement, influence, infrequently, investment, lack, leasing, lessee, longer, obtained, Oden, offered, package, pattern, permitted, Petito, policy, power, preceding, predecessor, proposed, qualify, recognizing, restatement, restating, retained, retroactively, Revocable, SEC, separate, SRT, Stuckert, succeeded, successor, Trust, unknown, unpaid